Clinical Trial Update: An Open-Label, FIH Study Evaluating the Safety, Tolerability, and Efficacy of VCTX211 Combination Product in Subjects With T1D [Phase 1, Phase 2]

View source ↗

Summary

Open-label, first-in-human Phase 1/Phase 2 trial evaluating the safety, tolerability, and preliminary efficacy of the VCTX211 Combination Product in people with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• VCTX211 Combination Product

Snippet

Sponsor: CRISPR Therapeutics AG | Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1 | Phase 1, Phase 2 | Status: RECRUITING